Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer

Open access
Byrd, Tiara T., Fousek, Kristen, Pignata, Antonella, Szot, Christopher, Samaha, Heba, Seaman, Steven, Dobrolecki, Lacey, Salsman, Vita S., Oo, Htoo Zarni, Bielamowicz, Kevin, Landi, Daniel, Rainusso, Nino, Hicks, John, Powell, Suzanne, Baker, Matthew L., Wels, Winfried S., Koch, Joachim, Sorensen, Poul H., Deneen, Benjamin, Ellis, Matthew J., Lewis, Michael T., Hegde, Meenakshi, Fletcher, Bradley S., St. Croix, Brad, Ahmed, Nabil · 2018 · Cancer Research

Abstract

Triple-negative breast cancer (TNBC) is an aggressive disease lacking targeted therapy. In this study, we developed a CAR T cell–based immunotherapeutic strategy to target TEM8, a marker initially defined on endothelial cells in colon tumors that was discovered recently to be upregulated in TNBC. CAR T cells were developed that upon specific recognition of TEM8 secreted immunostimulatory cytokines and killed tumor endothelial cells as well as TEM8-positive TNBC cells. Notably, the TEM8 CAR T cells targeted breast cancer stem–like cells, offsetting the formation of mammospheres relative to nontransduced T cells. Adoptive transfer of TEM8 CAR T cells induced regression of established, localized patient-derived xenograft tumors, as well as lung metastatic TNBC cell line–derived xenograft tumors, by both killing TEM8+ TNBC tumor cells and targeting the tumor endothelium to block tumor neovascularization. Our findings offer a preclinical proof of concept for immunotherapeutic targeting of TEM8 as a strategy to treat TNBC. Significance: These findings offer a preclinical proof of concept for immunotherapeutic targeting of an endothelial antigen that is overexpressed in triple-negative breast cancer and the associated tumor vasculature. Cancer Res; 78(2); 489–500. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-16-1911

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 160

Metadata

Authors
Byrd, T. T., Fousek, K., Pignata, A., Szot, C., Samaha, H., Seaman, S., Dobrolecki, L., Salsman, V. S., Oo, H. Z., Bielamowicz, K., Landi, D., Rainusso, N., Hicks, J., Powell, S., Baker, M. L., Wels, W. S., Koch, J., Sorensen, P. H., Deneen, B., Ellis, M. J., Lewis, M. T., Hegde, M., Fletcher, B. S., St. Croix, B., & Ahmed, N.
Venue
Cancer Research
Published
2018-01-15
Volume
78
Issue
2
Pages
489-500
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2768576952
Cited by
160
References
3
FWCI
4.85
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-1911
The paper
Byrd, T. T., Fousek, K., Pignata, A., Szot, C., Samaha, H., Seaman, S., Dobrolecki, L., Salsman, V. S., Oo, H. Z., Bielamowicz, K., Landi, D., Rainusso, N., Hicks, J., Powell, S., Baker, M. L., Wels, W. S., Koch, J., Sorensen, P. H., Deneen, B., . . . Ahmed, N. (2018). TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-1911

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.